Max Healthcare Institute · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
The institutional segment (government PSUs, CGHS, ECHS) showed flat ARPOB in Q2. While overall revenue was maintained, the lack of realization growth in this ~26-27% revenue segment could pressure margins if volume growth slows. Management attributed this to Dara hospital's ramp-up phase but acknowledged this is a structural consideration.
While the insurance impasse with three companies has been resolved (including agreement on future revisions), the company's 34-35% revenue exposure to TPA creates ongoing negotiation risk. The H2 renewal cycle includes other insurance companies. Any future impasses could again disrupt cashless facilities and shift patients to lower-margin self-pay channels.
Multiple peers are adding significant capacity in Lucknow and Noida markets where Max has existing operations. While management dismissed near-term competitive concerns (capacity takes 4-5 years to construct), the long-term market share dynamics in these high-growth metros remain uncertain.
When specifically asked about senior doctor departures from NCR hospitals, management provided only aggregate attrition data (<1% doctor attrition rate) without addressing whether any specific high-revenue specialists departed. The deflection with generic reassurance ('normal trend') suggests potential revenue risk if key specialists left for competitors, which was not transparently addressed.
